(Total Views: 332)
Posted On: 11/29/2019 3:24:49 AM
Post# of 145903
Thank you Trading ..ok early treatment most important , maybe this is why FDA was asking questions about pediatrics .
That reminded me about some other study , the Italian study with 40 patients in vitro , those patients were MDR -4. and they were resistant to Maraviroc ,
Well , apparently that too was not a problem for Leronlimab since they be presenting during CROI ..,,
We heard in the past that Leronlimab may work when patient resistant to Maraviroc ..
Wow , I honestly myself have a problems to see how this little molecules is working ...but I am so
proud I am a part of it ...,
Thank you ..
All in my opinion .
That reminded me about some other study , the Italian study with 40 patients in vitro , those patients were MDR -4. and they were resistant to Maraviroc ,
Well , apparently that too was not a problem for Leronlimab since they be presenting during CROI ..,,
We heard in the past that Leronlimab may work when patient resistant to Maraviroc ..
Wow , I honestly myself have a problems to see how this little molecules is working ...but I am so
proud I am a part of it ...,
Thank you ..
All in my opinion .
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)